A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant pro...
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
About this item
Full title
Author / Creator
Publisher
United States: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: Public Library of Science
Subjects
More information
Scope and Contents
Contents
Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of action include degrading constitutively active androgen receptor splice variants (AR-Vs) or inhibiting other drug-resistance pathways (e.g., Wnt-signaling). Published pharmacokinetics data sug...
Alternative Titles
Full title
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_2049517084
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2049517084
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0198389
